Eupraxia Pharmaceuticals Inc. (EPRX) stock
Close on Nov 13, 2026Market cap $491.40MP/E –Yield –
Eupraxia Pharmaceuticals Inc. reported revenue of $0 for fiscal 2025. At the latest close the market valued the company at $491.40M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $491.40M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.99
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$38.58M
- EPS, diluted
- -$1.03
Trading
- Previous close
- $7.81
- Open
- $7.81
- Day's range
- $7.61 – $8.23
- Volume
- 777,242
- Average volume (20 days)
- 589,288
- Beta (5 years)
- -0.02
- 52-week range
- $5.63 – $9.32
- RSI (14 days)
- 60.8
- Volatility (1 year)
- 65.1%
- Relative volume
- 1.34×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | EPRX | S&P 500 | Difference | EPRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +22.0% | -3.0% | +25.0 pts | ||
| 3 months | +22.2% | -2.8% | +25.0 pts | ||
| Year to date | +7.9% | +11.5% | −3.5 pts | ||
| 1 year | +28.5% | +13.5% | +15.1 pts | ||
| 3 years | +105.9% | +77.7% | +28.2 pts | +27.2% | +21.1% |
| 5 years | +262.2% | +72.6% | +189.6 pts | +29.4% | +11.5% |
Five years at a glance
Fiscal years 2021 to 2025, USD
Revenue
Net income
EPS, diluted
Press releases
Releases Eupraxia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Eupraxia Pharmaceuticals
Pharmaceutical Preparations
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of therapeutic candidates designed to address medical indications with high unmet need. The company utilizes proprietary drug delivery technology to optimize and extend the release profile of existing medications. Its primary product pipeline includes EP-104IAR, which targets joint-related inflammatory conditions such as osteoarthritis, and EP-104GI, which is directed toward gastrointestinal disorders. Rather than selling directly to commercial consumers, the company develops its product candidates for eventual healthcare use and collaborates through licensing agreements and clinical partnerships.
Company profile, executives and historyEupraxia Pharmaceuticals stock: common questions
What is Eupraxia Pharmaceuticals's stock price?
EPRX closed at $8.15 on Nov 13, 2026, up 4.35% on the day. Over the past 52 weeks it traded between $5.63 and $9.32.
What is Eupraxia Pharmaceuticals's market cap?
Eupraxia Pharmaceuticals was worth $491.40M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is EPRX's P/E ratio?
Eupraxia Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$1.03), so it has no meaningful P/E ratio.
How much revenue does Eupraxia Pharmaceuticals make?
Eupraxia Pharmaceuticals reported revenue of $0 for fiscal 2025.
Does Eupraxia Pharmaceuticals pay a dividend?
No. Eupraxia Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has EPRX stock performed over the past year?
Including dividends, EPRX returned +28.5% over the past year, against +13.5% for the S&P 500.
How many EPRX shares are sold short?
6M shares were sold short at the latest FINRA report, 11.47% of the float, or 10.4 days of average trading volume.
Who are Eupraxia Pharmaceuticals's competitors?
Companies most similar to Eupraxia Pharmaceuticals by business, industry and size include MSLE, RANI, XRTX, PBM, MNOV.
See a number that looks wrong?